Microglial activation and dopamine terminal loss in early Parkinson's disease

Annals of Neurology

Volumn 57, Issue 2, 2005, Pages 168-175

  Ouchi, Yasuomi ^a   Yoshikawa, Etsuji ^b   Sekine, Yoshimoto ^a,b   Futatsubashi, Masami ^b   Kanno, Toshihiko ^a   Ogusu, Tomomi ^b   Torizuka, Tatsuo ^a  

^a HAMAMATSU MEDICAL CENTER   (Japan)

^b CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DOPAMINE TRANSPORTER; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NALOXONE; OPIATE ANTAGONIST; TRACER;

ADULT; AGED; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL ACTIVATION; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPLEMENT FIXATION TEST; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; FEMALE; HUMAN; INFLAMMATION; MALE; MESENCEPHALON; MICROGLIA; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PREVALENCE; PRIORITY JOURNAL; PUTAMEN; RATING SCALE; STRIATONIGRAL DEGENERATION;

ADULT; AGE FACTORS; AGED; BRAIN; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICROGLIA; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PRESYNAPTIC TERMINALS;

EID: 13144258735     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20338     Document Type: Article

References (40)

1. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
2. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988;24:574-576.
3. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291.
4. Mirza B, Hadberg H, Thomsen P, Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 2000;95:425-432.
5. Vila M, Jackson-Lewis V, Guegan C, et al. The role of glial cells in Parkinson's disease. Curr Opin Neurol 2001;14:483-489.
6. Akiyama H, McGeer PL. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res 1989; 489:247-253.
7. Gao HM, Jiang J, Wilson B, et al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002;81:1285-1297.
8. Sherer TB, Betarbet R, Kim JH, Greenamyre JT. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 2003;341:87-90.
9. Sugama S, Yang L, Cho BP, et al. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 2003;964:288-294.
10. Langston JW, Forno LS, Tetrud J, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2,3,6 tetrahydropyridine exposure. Ann Neurol 1999;46:598-605.
11. McGeer PL, Schwab C, Parent A, Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Ann Neurol 2003;54:599-604.
12. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-318.
13. Conway EL, Gundlach AL, Craven JA. Temporal changes in glial fibrillary acidic protein messenger RNA and [3H]PK11195 binding in relation to imidazoline-I2-receptor and alpha 2-adrenoceptor binding in the hippocampus following transient global forebrain ischaemia in the rat. Neuroscience 1998;82:805-817.
14. Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123:2321-2337.
15. Cicchetti F, Brownell AL, Williams K, et al. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002;15:991-998.
16. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001;358:461-467.
17. Banati RB. Visualising microglial activation in vivo. Glia 2002; 40:206-217.
18. Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
19. Wullner U, Pakzaban P, Brownell AL, et al. Dopamine terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT. Exp Neurol 1994;126:305-309.
20. Ouchi Y, Yoshikawa E, Okada H, et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography. Ann Neurol 1999;45:601-610.
21. Watanabe M, Shimizu K, Omura T, et al. A new high resolution PET scanner dedicated to brain research. IEEE Trans Nucl Sci 2002;49:634-639.
22. Wong DF, Yung B, Dannals RF, et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse 1993;15:130-142.
23. Doraiswamy PM, Na C, Husain MM, et al. Morphometric changes of the human midbrain with normal aging: MR and stereologic findings. AJNR Am J Neuroradiol 1992;13:383-386.
24. Mai JK, Assheuer J, Paxinos G. Atlas of the human brain. San Diego: Academic Press, 1997.
25. Ouchi Y, Kanno T, Okada H, et al. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. Ann Neurol 1999; 46:723-731.
26. Lammertsma AA, Bench CJ, Hume SP, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 1996;16:42-52.
27. Gun R, Lammertsma AA, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference tissue model and cluster analysis. In: Carson R, Daule M, Witherspoon P, Herscovitch P, eds. Quantitative functional brain imaging with PET. San Diego, CA: Academic Press, 1998:401-406.
28. Boje KM, Arora PK. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res 1992;587:250-256.
29. Ehrlich LC, Hu S, Sheng WS, et al. Cytokine regulation of human microglial cell IL-8 production. J Immunol 1998;160:1944-1948.
30. McGuire SO, Ling ZD, Lipton JW, et al. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol 2001;169:219-230.
31. Banati RB, Cagnin A, Brooks DJ, et al. Long-term transsynaptic glial responses in the human thalamus after peripheral nerve injury. Neuroreport 2001;12:3439-3442.
32. Ouchi Y, Yoshikawa E, Futatsubashi M, et al. Effect of simple motor performance on regional dopamine release in the striatum in parkinson disease patients and healthy subjects: a positron emission tomography study. J Cereb Blood Flow Metab 2002;22:746-752.
33. Goerendt IK, Messa C, Lawrence AD, et al. Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain 2003;126:312-325.
34. Castano A, Herrera AJ, Cano J, Machado A. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem 2002;81:150-157.
35. Lipsky PE. The clinical potential of cyclooxygenase-2-specific inhibitors. Am J Med 1999;106:51S-57S.
36. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003;304:1-7.
37. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal antiinflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60:1059-1064.
38. McGeer PL, Schulzer M, McGeer EG. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-432.
39. Czlonkowska A, Kurkowska-Jastrzebska I, Czlonkowski A, et al. Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Med Sci Monit 2002;8:RA165-RA177.
40. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004; 291:358-364.